Research programme: pain therapeutics - Almirall/Esteve/Palau Pharma/ProteomikaAlternative Names: Neogenius Pharma project
Latest Information Update: 16 Jul 2016
At a glance
- Originator Almirall S.A.; Esteve; Palau Pharma; Proteomika
- Developer Almirall S.A.; ESTEVE; Palau Pharma; Proteomika
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Musculoskeletal pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in Spain
- 02 Mar 2010 Preclinical trials in Musculoskeletal pain in Spain (unspecified route)